Administration of zoledronic acid enhances the effects of docetaxel on growth of prostate cancer in the bone environment
about
Inhibition of Hsp90 augments docetaxel therapy in castrate resistant prostate cancerRegistered report: androgen receptor splice variants determine taxane sensitivity in prostate cancerZoledronic acid preserves bone structure and increases survival but does not limit tumour incidence in a prostate cancer bone metastasis modelImproving treatment strategies for patients with metastatic castrate resistant prostate cancer through personalized computational modeling.Direct antitumour activity of zoledronic acid: preclinical and clinical data.Inhibition of cathepsin activity in a cell-based assay by a light-activated ruthenium compound.The expression of osteoclastogenesis-associated factors and osteoblast response to osteolytic prostate cancer cells.Change in markers of bone metabolism with chemotherapy for advanced prostate cancer: interleukin-6 response is a potential early indicator of response to therapy.Antitumor activity of zoledronic acid in primary breast cancer cells determined by the ATP tumor chemosensitivity assay.Inhibition of angiopoietin-2 in LuCaP 23.1 prostate cancer tumors decreases tumor growth and viability.Doxorubicin-poly (ethylene glycol)-alendronate self-assembled micelles for targeted therapy of bone metastatic cancer.Drugs which inhibit osteoclast function suppress tumor growth through calcium reduction in bone.The prognostic utility of the transcription factor SRF in docetaxel-resistant prostate cancer: in-vitro discovery and in-vivo validation.PI-3K/Akt pathway-dependent cyclin D1 expression is responsible for arsenite-induced human keratinocyte transformation.A single administration of combination therapy inhibits breast tumour progression in bone and modifies both osteoblasts and osteoclasts.Mouse models for studying prostate cancer bone metastasis.Therapeutic strategies for bone metastases and their clinical sequelae in prostate cancer.Dasatinib inhibits the growth of prostate cancer in bone and provides additional protection from osteolysis.Serially heterotransplanted human prostate tumours as an experimental modelClinical efficacy and safety of zoledronic acid in prostate and breast cancer.Management of castration-resistant prostate cancer: bisphosphonates and emerging therapies.RAD001 (Everolimus) inhibits growth of prostate cancer in the bone and the inhibitory effects are increased by combination with docetaxel and zoledronic acidSpheroid culture of LuCaP 136 patient-derived xenograft enables versatile preclinical models of prostate cancer.Bisphosphonate-Functionalized Imaging Agents, Anti-Tumor Agents and Nanocarriers for Treatment of Bone Cancer.Effect of artemisinin derivatives on apoptosis and cell cycle in prostate cancer cells.Zoledronic acid increases docetaxel cytotoxicity through pMEK and Mcl-1 inhibition in a hormone-sensitive prostate carcinoma cell line.The hedgehog pathway conditions the bone microenvironment for osteolytic metastasis of breast cancer.
P2860
Q28541342-3348BB02-FDC8-47CB-A69E-C8A65F6E86F4Q28607383-424585C3-A25C-4C91-A606-6A615B0039D1Q28744548-2F1CEE74-BFE8-49B7-A681-8FBC3DBAFCEAQ33589156-287D1122-BD3E-4CC0-B5AD-801379DB3746Q33850938-9CBED171-12A4-471A-B9D6-88D2A3CEF0CFQ33893128-65472730-EA09-4E86-A623-747CCA914BC1Q34087187-7C6F6781-EA19-4896-9C67-22AD841B1EC4Q34207923-5492AF33-9BAE-499F-972D-8A8F0C37264AQ34348233-49EC6C75-C4B1-4DFC-9D75-C15DCB8716ACQ35014686-0B79F432-E11F-4C71-9D45-9C6624E665B1Q36106734-1E1FB4ED-33C6-4BBC-ABAA-F4317C1D2A67Q36278275-9E949A6A-9E4C-4E9C-8C20-29E9323EC8A7Q36294460-2C797E01-3239-407D-B51D-3863D4112BD1Q36381304-35A81639-4009-40A0-B47F-15D97D387105Q36491378-E7F29681-7A58-4EEA-A57A-DF9A99266B2AQ36590497-E607FE08-6303-4C37-9BE1-22D97C16AE3EQ36840731-3100EEE4-622C-45DB-8A0A-1C33D42A830DQ37287442-694DF097-7F68-4817-BF73-A25C729AADEFQ37310963-2F0ADA5B-E57A-416C-BFE3-69C1C333B13EQ37598932-63FBD79E-2454-44B8-8344-03C512FF7657Q37812612-13728775-1C16-43CD-9949-13997AAF4090Q38263467-5EB6A682-6E20-42EE-8A27-C29D5C65EB7CQ38794482-DB6E2491-2ECA-4637-AAB4-CFC03523531FQ39138688-92DC4138-0E45-4368-B211-E8D0286FB85DQ39744038-F62010DB-4C52-4DFA-B7AE-911727BF8156Q39952307-ECB2E73C-AF94-4581-B7C9-8C836EDC902BQ40548535-565DD812-381D-4D98-ABC8-FF1E8194C179
P2860
Administration of zoledronic acid enhances the effects of docetaxel on growth of prostate cancer in the bone environment
description
2006 nî lūn-bûn
@nan
2006 թուականի Յունուարին հրատարակուած գիտական յօդուած
@hyw
2006 թվականի հունվարին հրատարակված գիտական հոդված
@hy
2006年の論文
@ja
2006年論文
@yue
2006年論文
@zh-hant
2006年論文
@zh-hk
2006年論文
@zh-mo
2006年論文
@zh-tw
2006年论文
@wuu
name
Administration of zoledronic a ...... cancer in the bone environment
@ast
Administration of zoledronic a ...... cancer in the bone environment
@en
Administration of zoledronic a ...... cancer in the bone environment
@nl
type
label
Administration of zoledronic a ...... cancer in the bone environment
@ast
Administration of zoledronic a ...... cancer in the bone environment
@en
Administration of zoledronic a ...... cancer in the bone environment
@nl
prefLabel
Administration of zoledronic a ...... cancer in the bone environment
@ast
Administration of zoledronic a ...... cancer in the bone environment
@en
Administration of zoledronic a ...... cancer in the bone environment
@nl
P2093
P2860
P356
P1433
P1476
Administration of zoledronic a ...... cancer in the bone environment
@en
P2093
Kristen D Brubaker
Lisha G Brown
Robert L Vessella
P2860
P2888
P356
10.1186/1471-2407-6-15
P407
P577
2006-01-17T00:00:00Z
P5875
P6179
1026159711